European Society of Cardiology Congress September 3-7, 2005, Stockholm
Michael Petch, Papworth Hospital, Cambridge
Man Fai Shiu, Walsgrave Hospital, Coventry
James Tcheng, Duke University, Durham
Harvey White, Green Lane Hospital, Auckland
Producer: Derek Thorne
In this edition:
The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress. Keith Fox talked about new evidence that strengthens the case for aggressive management of patients.
The conference also heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578. Jean Fajadet from Toulouse discussed the ENDEAVOR-2 study.
A future option for treating in-stent restenosis by coating a balloon with an anti-proliferative drug and inflating it inside the newly-occluded stent was discussed at the ESC Congress by Bruno Scheller who presented the first study of such a device in humans.
In the treatment of acute myocardial infarction, the 24-country ASSENT-4 study seems to show an overall increase of risk if you use thrombolysis before primary PCI. Frans Van de Werf gave the 30 day analysis. Kim Fox comments.
Shamir Mehta, McMaster University, Hamilton Ontario
Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questioned Freek Verheugt of Nijmegen.
COMMENT: Freek Verheugt, Academisch Ziekenhuis, Nijmegen, The Netherlands
Shamir Mehta: [audio:http://184.108.40.206/podcasting/08.Shamir_Mehta.mp3] Freek Verheugt: [audio:http://220.127.116.11/podcasting/09.Freek_Verheugt.mp3]
Keith Fox, Edinburgh Royal Infirmary
The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress. Keith Fox from Edinburgh told Audio Medica about new evidence that strengthens the case for aggressive management.
Peter Sever, Imperial College, National Heart & Lung Institute, London
Jean Fajadet, Unite de Cardiologie Interventionnelle, Toulouse
The ESC heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578. Jean Fajadet from Toulouse told Audio Medica about the findings from ENDEAVOR II study of around 1200 patients.